Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

The British Journal of Dermatology
Alexa B KimballKim Papp

Abstract

An unmet need remains for safe and effective long-term treatments of psoriasis. To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 trial. Patients (n = 766) with moderate-to-severe psoriasis were randomized to ustekinumab 45 mg or 90 mg at weeks 0 and 4, and then every 12 weeks, or placebo at weeks 0 and 4, with crossover to ustekinumab at week 12. Ustekinumab responders [≥ 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) at weeks 28 and 40] were re-randomized at week 40 to continue or withdraw from treatment until psoriasis recurrence. Partial responders (week 28: PASI 50-74; week 40: < PASI 75) switched to dosing every 8 weeks. Clinical efficacy was assessed by PASI, the Physician's Global Assessment (PGA), and the Dermatology Life Quality Index (DLQI) measures. Overall, 79·8% of the ustekinumab-treated patients remained in the study for 3 years. PASI 75 response rates (45 mg: 61·2%; 90 mg: 72·4%) at week 76 were maintained through year 3 (45 mg: 62·7%; 90 mg: 72·2%); PGA response was similarly durable. At year 3, 80·9% (45 mg) and 82·7% (90 mg) of week 40 responders continuing treatment every 12 weeks achieved a PASI 75 response, while 42·6% (45 mg) and 58·0% (90 mg...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Apr 12, 1979·The New England Journal of Medicine·R S SternT B Fitzpatrick
May 3, 1984·The New England Journal of Medicine·R S SternH L Bleich
Aug 1, 1981·Archives of Dermatology·M R PittelkowP C O'Brien
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Feb 1, 1996·Journal of the American Academy of Dermatology·M A MenterM D Zanolli
Feb 24, 2001·Health Technology Assessment : HTA·C E GriffithsH C Williams
Jul 26, 2003·The Journal of Investigative Dermatology·Tamar E C Nijsten, Robert S Stern
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
May 22, 2004·Journal of the American Academy of Dermatology·Christopher S CarlinGerald G Krueger
Sep 25, 2004·Journal of the American Academy of Dermatology·Alice B GottliebAlan Menter
Jun 14, 2005·The British Journal of Dermatology·K A PappUNKNOWN Etanercept Psoriasis Study Group
Feb 21, 2006·Journal of the American Academy of Dermatology·Wayne CareyDarryl Toth
Feb 9, 2007·The New England Journal of Medicine·Gerald G KruegerUNKNOWN CNTO 1275 Psoriasis Study Group
Sep 15, 2007·Autoimmunity Reviews·Paolo Gisondi, Giampiero Girolomoni
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Oct 7, 2008·The British Journal of Dermatology·R M R HearnR S Dawe
Oct 23, 2009·Dermatologic Therapy·Eihab A AlwawiKenneth B Gordon
Jan 15, 2010·The New England Journal of Medicine·Christopher E M GriffithsUNKNOWN ACCEPT Study Group
Sep 3, 2010·Dermatology : International Journal for Clinical and Investigative Dermatology·M PapoutsakiS Chimenti
Sep 21, 2010·Journal of the American Academy of Dermatology·Kim A PappJerry Syrotuik
Nov 13, 2010·Clinical and Experimental Dermatology·V Di Lernia
Jul 26, 2011·The Journal of Dermatological Treatment·Vito Di LerniaGiuseppe Albertini

❮ Previous
Next ❯

Citations

May 17, 2013·American Journal of Clinical Dermatology·Kara N Shah
Dec 12, 2012·Nature Reviews. Rheumatology·Tony J Kenna, Matthew A Brown
Jun 3, 2014·Journal of Immunology Research·Leeyen Hsu, April W Armstrong
Apr 30, 2014·American Journal of Clinical Dermatology·Esther de EusebioVíctor Alegre de Miquel
Nov 20, 2012·Annual Review of Pathology·Casey T WeaverJay K Kolls
Jul 3, 2013·Actas dermo-sifiliográficas·P Soro MartínezM P Arribas Granados
Nov 14, 2015·Annual Review of Medicine·George E FragoulisIain B McInnes
Jan 6, 2015·The British Journal of Dermatology·B B JonesK Callis Duffin
Oct 25, 2012·The British Journal of Dermatology·J Leman, A D Burden
Jul 25, 2012·Annals of the New York Academy of Sciences·Newman YeildingCynthia Guzzo
Jan 3, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·A B KimballUNKNOWN PHOENIX 1 Investigators
Oct 15, 2013·The British Journal of Dermatology·P RichUNKNOWN PHOENIX 1 investigators
Jan 1, 2014·Journal of the American Academy of Dermatology·Adriane A Levin, Alice B Gottlieb
Mar 3, 2015·Pediatric Dermatology·Mohn'd AbuHilal, Nhung Ho
May 18, 2016·The Journal of Dermatological Treatment·Simona BartosSteven R Feldman
Oct 11, 2016·Expert Review of Clinical Immunology·M GalluzzoM Talamonti
May 4, 2017·Expert Opinion on Drug Metabolism & Toxicology·M GalluzzoL Bianchi
May 22, 2016·Journal of Cutaneous Medicine and Surgery·Melinda GooderhamKim Papp
Mar 20, 2016·Toxicologic Pathology·Dimitry M Danilenko
Feb 10, 2018·International Journal of Molecular Sciences·Marie-Astrid BoutetCostantino Pitzalis
Sep 25, 2018·International Journal of Dermatology·Shivani B Kaushik, Mark G Lebwohl
Aug 3, 2013·The Journal of Rheumatology·April W ArmstrongEhrin J Armstrong
Jun 6, 2019·Anais Brasileiros De Dermatologia·Marcelo ArnoneTatiana Jerez Jaime
Jan 10, 2020·The Cochrane Database of Systematic Reviews·Emilie SbidianLaurence Le Cleach
Sep 21, 2020·The British Journal of Dermatology·M C JohnsonS R Feldman
Sep 24, 2020·Inflammatory Bowel Diseases·William J SandbornSubrata Ghosh
May 26, 2018·Alimentary Pharmacology & Therapeutics·W J SandbornB G Feagan
Jul 9, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·A Al-HammadiN Tarcha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.